<DOC>
	<DOC>NCT00762346</DOC>
	<brief_summary>A multicenter prospective study to assess the efficacy and safety of ZOMETA® in treatment of high-level NTX non small cell lung cancer with bone metastasis.</brief_summary>
	<brief_title>Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>Age &gt; 18 Histologically confirmed nonsmall cell cancer One bone metastasis at least confirmed by image(X ray, CT or others) NTX &gt; 50nM BCE/mM creatinine Life expectancy &gt; 6 M ECOG &lt;= 2 Signed ICF Women who are pregnant or in lactation Patients with hyperostosis with brain metastasis(exception of those without symptom or with Metastasis Lesions under controlled Previous or current treatment with any other bisphosphonates, bone protecting, cytotoxic or targeted therapy Severe comorbidity of any type that may interfere with assessment of the patient for the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>non small cell lung cancer</keyword>
	<keyword>NTX</keyword>
	<keyword>zometa</keyword>
</DOC>